Precision Vaccinology for Public Health

Dear Colleagues,

In recent years, the field of precision vaccinology has gained prominence as an essential component in the quest to enhance public health strategies. Vaccines have been developed to treat entire populations with little provision for individual host factor differences.

Vaccination is one of the most effective methods to date and is one of the most cost-effective strategies for preventing infectious diseases. However, due to the increased number of vaccine non-responders and vaccine-relapsed individuals, it is important to deeply explore the challenges faced by more-at-risk groups for whom the benefits of personalized vaccination would be substantial. Indeed, it has been seen that not everyone responds equally to vaccination in terms of both risks (side effects) and benefits (non-infection or non-relapse).

Precision vaccinology can develop personalized immunization strategies that are based on the patient's immune system. Personalized vaccination can help to achieve global health equity. Some personalization is already in place, such as free or priority vaccination for at-risk groups of patients. This, among other things, can serve to avoid wasting important economic resources. Customization also concerns dosage, the interval between doses, and possible recalls, as well as age (e.g., individuals younger than one year of age or elderly have a deficient immune system), gender, genetic polymorphisms, tumors, asplenism, and pregnant women.

To fill these gaps, The aim of this Special to advance public health practices, promote public understanding of vaccine literacy by embracing personalized vaccination strategies, vaccine surveillance, and global health equity, ultimately improving health outcomes on a global scale. We welcome the submission of original research, review, perspective, and clinical trial articles, focusing on, but not limited to, the following sub-topics:

• Personalized vaccination strategies
• Vaccine surveillance
• Understanding and advancing vaccine literacy
• Global health equity
• Rapid response to emerging pathogens
• Vaccine hesitancy mitigation.

We look forward to your valuable contributions to this significant endeavor.

Warm regards,
Prof. Alessandra Casuccio
Dr. Palmira Immordino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• precision vaccinology
• public health
• vaccines
• vaccine-relapsed individuals
• personalized vaccination strategies
• vaccine surveillance
• vaccine literacy
• global health equity
• immune response to emerging pathogens
• vaccine hesitancy